Executive Summary
A JACC Advances meta-analysis of 52 studies lands the clearest verdict yet on bicuspid TAVR: procedural risk runs higher than tricuspid anatomy (PVL RR 1.44, root injury RR 1.83, 30-day mortality RR 1.25), yet 1-year mortality is lower — a signal driven by patient selection, not valve performance. Meanwhile, Cardiovascular Business headlines that surgery beats TAVR in young patients, reinforcing the ACC/AHA <65 SAVR-preferred zone that ESC 2025 pushed to <70. A 1,032-patient Bern cohort in JACC Advances shows suboptimal balloon-expandable deployment tripled 30-day safety events and quadrupled 5-year stage-2 bioprosthetic valve failure — the durability argument for TAVR in younger patients is only as good as the operator. Together, today complicates the case for indication creep toward younger anatomy.
- Transcatheter TR: Mayo 100-patient comparison shows TEER favors RV remodeling; TTVR delivers more complete TR elimination and higher forward stroke volume.
- MitraClip G4 and PASCAL are a tie at 1 year in FMR — propensity-matched 232 patients, identical survival (86.7% vs 87.8%) and MR reduction.
- Sex differences in M-TEER outcomes disappear at 6 months despite women presenting older and sicker — N=293 single-center cohort.
- FDA Early Alert on Medtronic Bravo pH capsule and a separate recall of all Impella controllers after 3 deaths — a bruising 48 hours for the device pipeline.
- HighLife earned CE Mark for its next-gen Clarity TMVR valve, keeping European TMVR access ahead of the US.
What to watch: Medtronic reports Q1 earnings September 1 — TAVR volumes, Evolut low-risk mix, and any commentary on the Impella controller recall's cardiac franchise spillover.
Aortic Valve (TAVR/TAVI)
Two studies this morning sharpen the durability-and-selection tension that has defined the low-risk expansion debate. The Bern cohort (N=1,032, Sapien S3/Ultra, single-center, non-randomized) found that 43% of implants met at least one criterion for suboptimal deployment — noncoaxial (23%), too deep (25%), or underexpanded (5%). Suboptimal implantation tripled the 30-day modified safety endpoint (43.3% vs 19.9%) and quadrupled 5-year stage 2 bioprosthetic valve failure (subHR 4.40). [NOTABLE] This is the strongest procedural-quality-to-durability link published to date and undercuts the assumption that "TAVR is TAVR" across centers. ACC/AHA 2020 still recommends SAVR for patients <65 (Class I) and ESC 2025 raised that floor to <70; the Bern data give both guidelines cover — if 4-in-10 low-risk implants aren't optimal, the case for delaying to age 70 is stronger, not weaker.
The 52-study bicuspid meta-analysis confirms BAV TAVR carries higher paravalvular leak (RR 1.44), aortic root injury (RR 1.83), and 30-day stroke (RR 1.27) versus tricuspid anatomy, though 1-year mortality is lower — a selection artifact, not a valve win. Compared with SAVR in BAV, TAVR had 7-fold higher PVL (RR 7.08) with no early mortality advantage. Both ACC/AHA 2020 and ESC 2025 keep BAV TAVR at Class IIb; nothing here challenges that. A 385-patient OCEAN-TAVI analysis of extremely small annuli (<314 mm²) found broadly similar outcomes across balloon-expandable, supra-annular self-expanding, and intra-annular self-expanding platforms, with a numeric PVL signal favoring BEV (15.8% vs 27%). A 172-patient anatomy-tailored commissural alignment technique for Evolut FX cut moderate/severe misalignment from 30% to 14% — a low-cost tweak with real implications for future valve-in-valve access.
JACC Advances flagged rising middle-aged AS mortality and widening rural disparities in the TAVR era — access, not technology, is the story in that population.
Mitral Valve (MitraClip, PASCAL, TMVR)
MitraClip G4 vs PASCAL is a coin flip in functional MR. The Leipzig propensity-matched cohort (116 pairs, single-center, non-randomized) found identical procedural success (98.1% vs 97.3%), 1-year survival (86.7% vs 87.8%), and freedom from HF rehospitalization. Operators can pick on anatomy and cost, not outcomes. This sits comfortably against ESC 2025's Class I recommendation for TEER in ventricular SMR meeting COAPT criteria — the ACC/AHA 2020 Class IIa lags behind. A separate 293-patient M-TEER cohort found women present older, more symptomatic, and with worse baseline 6-minute walk — but 6-month mortality (17% vs 22%) and HF rehospitalization tracked identically. Referral timing, not device response, is the sex-gap driver.
On the surgical side, guideline direction still favors mitral repair over TEER for primary MR — ESC 2025 upgraded early asymptomatic PMR surgery to Class I when 3+ risk factors are present (AF, SPAP >50, LA dilation, ≥moderate TR). Today's data are entirely secondary MR; the surgical comparator remains unchallenged in primary disease. A Bayesian meta-analysis of TEER for secondary MR in HF was published in JACC Advances — abstract unavailable, but it will land in the same COAPT/RESHAPE-HF2/MITRA-FR triangulation ESC used to justify its Class I upgrade.
Tricuspid Valve (TriClip, TTVR)
The Mayo Clinic 100-patient invasive-hemodynamics study (50 TEER vs 50 TTVR, single-center, non-randomized, 2017-2024) is the most granular head-to-head on transcatheter TR modality choice to date. [NOTABLE] TEER reduced mean RA pressure (16→14 mm Hg) and V wave, with RV enlargement falling from 60% to 40% and RV dysfunction trending down (26%→15%). TTVR eliminated TR more completely and delivered higher forward stroke volume, but RV dysfunction actually rose (31%→44%). The signal: TEER unloads the RV; TTVR volume-loads it while curing regurgitation. NYHA improvement and survival tracked similarly. This will not settle the repair-vs-replace question — TRISCEND II already showed TTVR wins on symptoms — but it tells the Heart Team that patients with borderline RV function may fare better with TEER than with the "definitive" replacement.
ESC 2025 gives transcatheter TV treatment Class IIa (LOE A) for high-risk symptomatic severe TR with preserved RV function, based on TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II. ACC/AHA 2020 gives no recommendation because the trials hadn't read out. The Mayo data support the ESC framing but add a modality-selection nuance the guidelines don't yet capture.
Surgical vs. Transcatheter Comparisons
Cardiovascular Business's lead this week is that surgery bests TAVR in young patients — an editorial framing that lines up with the Bern durability data and with both current guidelines. The specifics matter: ACC/AHA 2020 favors SAVR at <65 (Class I), ESC 2025 pushed the SAVR-preferred zone to <70. In BAV specifically, today's meta-analysis found no mortality advantage for TAVR vs SAVR at 30 days and 7-fold higher PVL — SAVR remains the default answer for young BAV patients with aortopathy. The COMPARE-TAVI 1 Lancet correction tightens the reported Sapien 3 vs Myval risk difference (–1.2%, one-sided lower 95% CI –4.7) — a data-integrity nudge, not a signal shift.
Device & Technology
HighLife's CE Mark approval for Clarity — the next-generation valve in its transseptal TMVR system — advances European TMVR access ahead of the US, where dedicated TMVR remains investigational and TEER dominates. HighLife is private; no market read. Case-report technique work in JACC Case Reports this week covered bioprosthetic valve fracture for VIV TAVR planning, the BATMAN leaflet modification for ViMAC eligibility, and balloon-based sizing adjuncts for bicuspid BEV TAVR — the kind of procedural craftsmanship that separates high-volume centers from the median. LAAO device embolization retrieval strategies were also profiled — 4 cases across left atrial, aortic, and delayed embolization, with the reminder that surgical backup remains non-negotiable.
Regulatory & Policy
Two regulatory events dominate: FDA announced a recall of all Impella heart pump controllers after 3 deaths — Abiomed/J&J franchise territory, adjacent to but not squarely inside structural heart, though the same interventional labs are affected. Separately, the FDA issued an Early Alert on Medtronic's Bravo CF esophageal pH capsule delivery device, with 184 serious injuries reported. Not a cardiac device, but a second Medtronic quality event landing the week before earnings.
Industry & Market
Filings show CPP Investment Board added 798,740 EW shares, Bamco NY opened a $20.77M EW position, and Freestone Grove invested $15.48M. Institutional accumulation continues around $90 as EW consolidates post-earnings. Insider selling is present but modest: CVP Daveen Chopra sold $2.9M and CVP Wayne Markowitz sold $113K.
Financial Analysis
The clinical story pulls one way, the tape pulls another. Today's data — Bern deployment quality, BAV meta-analysis, "surgery bests TAVR in young patients" — should compress the low-risk expansion narrative. Yet institutional capital continues to flow into EW on the read that TR (Evoque, PASCAL Ace) and MR franchise durability underpin the multi-year story regardless of the AS growth ceiling. BSX is the tell: down nearly 39% over six months, well past what the Impella controller recall alone explains. The market is pricing broader concern about device franchise execution, and the FDA action on all Impella controllers today extends that. MDT sits at $89.97 heading into Monday's Q1 print with a modest 6-month decline of 6.7% — the Bravo Early Alert adds noise but doesn't touch structural heart. If Medtronic tags Evolut low-risk mix and TAVR ASP into the print, that's the print's real signal.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Price: $89.95 (-0.91%); 6-month +3.18%; range $76.49-$96.29
- Market cap: $51.8B | P/E trailing 54.2, forward 26.6 | Beta 0.85 | 52-wk $72.30-$96.29
- Analyst target: $100.96 (n=26) — buy consensus
- Next earnings: Oct 29 (EPS est $0.74, revenue $1.68B)
- Commentary: Institutional accumulation continues (CPP, Bamco, Freestone Grove, Palo Alto Investors all filed adds this week). Stock consolidating near $90 post-earnings. TR franchise (Evoque) and Ace PASCAL positioning drive the multi-year story; today's BAV meta-analysis and Bern deployment data are modest headwinds for the low-risk narrative but well-priced.
Medtronic (MDT)
- Price: $89.97 (-2.23%); 6-month -6.70%; range $72.65-$97.09
- Market cap: $115.2B | P/E trailing 24.1, forward 14.1 | Beta 0.57 | 52-wk $73.31-$106.33
- Analyst target: $97.92 (n=25) — buy consensus
- Next earnings: Sep 1 (EPS est $1.39, revenue $9.54B)
- Commentary: Monday's print is the near-term catalyst. Bravo pH capsule Early Alert is non-cardiac and unlikely to move guidance, but adds to a run of quality events. Evolut FX commissural alignment work published today is a positive procedural narrative for the platform ahead of the call.
Abbott (ABT)
- Price: $111.59 (-2.20%); 6-month -0.90%; range $81.39-$117.34
- Market cap: $194.4B | P/E trailing 36.1, forward 18.4 | Beta 0.58 | 52-wk $81.97-$137.49
- Analyst target: $120.20 (n=25) — buy consensus
- Next earnings: Oct 14 (EPS est $1.42, revenue $12.99B)
- Commentary: Today's MitraClip G4 vs PASCAL functional MR study shows a dead heat at 1 year — durable for Abbott but reinforces that Edwards has closed the gap on TEER for FMR. TriClip momentum remains the structural heart story.
Boston Scientific (BSX)
- Price: $46.67 (-3.11%); 6-month -38.77%; range $42.20-$76.68
- Market cap: $67.6B | P/E trailing 19.5, forward 13.6 | Beta 0.57 | 52-wk $42.20-$109.50
- Analyst target: $62.69 (n=29) — buy consensus (target 34% above current)
- Next earnings: Oct 28 (EPS est $0.81, revenue $5.26B)
- Commentary: The chart is a mess. Six-month drawdown of 39% is well past normal medtech volatility. Analyst target implies value if execution recovers; stock trades near 52-week low.
Anteris Technologies (AVR.AX)
- Price: A$12.35 (+1.48%); 6-month +40.34%; range A$7.13-A$15.47
- Market cap: A$1.2B | Forward P/E -5.7 | 52-wk A$5.20-A$15.47
- Commentary: Best 6-month performance in the group as DurAVR clinical readouts advance. Single-analyst coverage limits conviction; a specialty story.
Sector view: EW is the anchor holding, MDT is event-driven into Monday, ABT is diversified insulation, BSX is broken, AVR.AX is a specialty single. The structural heart thesis remains intact but is bifurcating: TR growth is real and near-term (ESC 2025 Class IIa upgrade), AS low-risk expansion faces guideline resistance in both regions, and TMVR remains a European-first market.
Clinical Trial Updates
Light day for structural trial registry changes.
- Imaging/access: NCT07788040 — Intracardiac Echocardiography Catheter Supply-Chain Reliability and Clinical Access Study | Not yet recruiting | N=200 | Truway Health. Not a valve trial per se but ICE access underpins TEER and TTVR workflows.
No registry changes today for landmark trials (EARLY TAVR, PARTNER, Evolut Low Risk, COAPT, RESHAPE-HF2, TRILUMINATE, Tri.Fr, TRISCEND II, REPAIR-MR, PRIMARY, APOLLO). Watch for ESC Congress simultaneous-publication trials landing over the weekend.
Social & Conference Highlights
ESC Congress is running through September 2. Late-breaking valve sessions in the coming days should include follow-up analyses on TR TEER durability and additional readouts on early intervention in asymptomatic AS. Cardiovascular Business's "surgery bests TAVR in young patients" framing is circulating on interventional Twitter as the counterweight to the ESC 2025 age-70 shift for TAVI.
What next: Medtronic's Q1 print Monday morning is the immediate catalyst; ESC late-breaking valve sessions run through Tuesday. Watch whether any TR device readout or an asymptomatic AS follow-up lands with a simultaneous NEJM or Lancet publication — that's where guideline pressure builds.
— E. Nolan Beckett, MD
The Valve Wire